Abstract
Mutant TP53 is an adverse risk factor in acute myeloid leukemia (AML), but large-scale integrated genomic-proteomic analyses of TP53 alterations in pa......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
